N@N

MannKind to Present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference

^{Published on 2010-12-01 17:20:34 - Market Wire}
 

VALENCIA, Calif.--([ BUSINESS WIRE ])--MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Genuity 5^th Annual Cardiovascular, Diabetes & Obesity Conference on Wednesday, December 8, 2010 at 10:00 AM (PT) at the Nikko Hotel in San Francisco, CA.

Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at [ http://www.mannkindcorp.com ].

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA® and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy platform MKC1106, which is currently in phase 2 clinical trials. MannKind maintains a website at [ http://www.mannkindcorp.com ] to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.